Á¶¿ïÁõ ±âºÐ ¾ÈÁ¤Á¦ ½ÃÀå : ¾àÁ¦ À¯Çüº°, ÀûÀÀÁõº°, Åõ¿© °æ·Îº°, ȯÀÚ ¼Ó¼ºº°, À¯Åë ä³Îº°, Áö¿ªº°
Bipolar Disorder Mood Stabilizers Market, By Drug Type, By Indication, By Route of Administration, By Patient Demographics, By Distribution Channel, By Geography
»óǰÄÚµå
:
1747313
¸®¼Ä¡»ç
:
Coherent Market Insights
¹ßÇàÀÏ
:
2025³â 05¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹®
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¼¼°èÀÇ Á¶¿ïÁõ ±âºÐ ¾ÈÁ¤Á¦ ½ÃÀåÀº 2025³â¿¡´Â 22¾ï 2,000¸¸ ´Þ·¯, 2032³â±îÁö´Â 26¾ï 4,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025-2032³â ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)Àº 2.5%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
º¸°í¼ ¹üÀ§ |
º¸°í¼ »ó¼¼ |
±âÁØ ¿¬µµ |
2024³â |
2025³â ½ÃÀå ±Ô¸ð |
22¾ï 2,000¸¸ ´Þ·¯ |
½ÇÀû µ¥ÀÌÅÍ |
2020-2024³â |
¿¹Ãø ±â°£ |
2025-2032³â |
¿¹Ãø ±â°£(2025-2032³â) CAGR |
2.50% |
2032³â ±Ý¾× ¿¹Ãø |
26¾ï 4,000¸¸ ´Þ·¯ |
Á¶¿ïÁõÀ¸·Îµµ ¾Ë·ÁÁø ¾ç±Ø¼º Àå¾Ö´Â ±âºÐ, ¿¡³ÊÁö, Ȱµ¿ ¼öÁØ, ÀÏ»ó ¾÷¹« ¼öÇà ´É·Â¿¡ ºñÁ¤»óÀûÀÎ º¯È¸¦ ÀÏÀ¸Å°´Â ³ú ÁúȯÀÔ´Ï´Ù. Ç׿ì¿ïÁ¦´Â ¾ç±Ø¼º Àå¾Ö·Î ÀÎÇÑ ±Ø´ÜÀûÀÎ ±âºÐ º¯È¸¦ ¿¹¹æÇϰųª Ä¡·áÇϱâ À§ÇØ »ç¿ëµÇ´Â ¾à¹°ÀÇ ÀÏÁ¾ÀÔ´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î ¾ç±Ø¼º Àå¾ÖÀÇ À¯º´·üÀÌ Áõ°¡Çϰí È¿°úÀûÀÎ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó, ¼¼°è ¾ç±Ø¼º Àå¾Ö ±âºÐ ¾ÈÁ¤Á¦ ½ÃÀåÀº Áö³ ¸î ³â µ¿¾È Å« °ßÀÎÂ÷ ¿ªÇÒÀ» ÇØ¿Ô½À´Ï´Ù. ¶ÇÇÑ, »õ·Î¿î Ä¡·á¹ýÀ» °³¹ßÇϱâ À§ÇÑ Á¦¾à»çµéÀÇ R&D ÅõÀÚ Áõ°¡µµ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.
½ÃÀå ¿ªÇÐ
¼¼°è ¾ç±Ø¼º Àå¾Ö ±âºÐ ¾ÈÁ¤Á¦ ½ÃÀåÀº ÁÖ·Î À¯ÀüÀû ¿äÀΰú ¿Ü»ó¼º »ýȰ »ç°Ç ¹× ¾à¹° ³²¿ë°ú °°Àº ȯ°æÀû ¿äÀÎÀ¸·Î ÀÎÇÑ ¾ç±Ø¼º Àå¾ÖÀÇ À¯º´·ü Áõ°¡¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖÀ¸¸ç, 2024³â 7¿ù¿¡ ¹ßÇ¥µÈ WHO Åë°è¿¡ µû¸£¸é Àü ¼¼°èÀûÀ¸·Î 4,500¸¸ ¸í ÀÌ»óÀÌ ¾ç±Ø¼º Àå¾Ö¸¦ ¾Î°í ÀÖ´Ù°í ÇÕ´Ï´Ù. À» ¾Î°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, »ç¿ë °¡´ÉÇÑ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ÀÇ·áºñ ÁöÃâÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ´õ ¸¹Àº ȯÀÚµéÀÌ ÀÇ·á Áö¿øÀ» ¿äûÇϰí ÀÖ½À´Ï´Ù. ÇÑÆí, Áö¼ÓÀûÀÎ ±â¼ú Çõ½Å°ú ´õ È¿°úÀûÀÌ°í ³»¾à¼ºÀÌ °³¼±µÈ »õ·Î¿î ¾à¹° Á¦Á¦ÀÇ µµÀÔÀº ½ÃÀå È®´ë¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª Àú°³¹ß±¹¿¡¼´Â Á¤½ÅÀå¾ÖÀÇ Áø´Ü ¹× Ä¡·áÀ²ÀÌ ³·±â ¶§¹®¿¡ ½ÃÀå ÀáÀç·ÂÀº ¾ÆÁ÷ ¹Ì°³Ã´ »óÅÂÀÔ´Ï´Ù. ¶ÇÇÑ, ºê·£µå ÀǾàǰÀÇ ³ôÀº ºñ¿ëµµ °¡°Ý¿¡ ¹Î°¨ÇÑ ½ÃÀå¿¡¼ÀÇ Ã¤ÅÃÀ» Á¦ÇÑÇϰí ÀÖ½À´Ï´Ù. ±×·³¿¡µµ ºÒ±¸Çϰí, ƯÈ÷ Ä¡·á ÀúÇ×¼º ȯÀÚ¸¦ ´ë»óÀ¸·Î ÇÑ Ã·´Ü ¾à¹°¿¡ ´ëÇÑ ÀÓ»ó½ÃÇèÀÌ ÁøÇà ÁßÀ̱⠶§¹®¿¡ ¿¹Ãø ±â°£ µ¿¾È »õ·Î¿î ±âȸ°¡ âÃâµÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡
- ¼¼°èÀÇ ¾ç±Ø¼º Àå¾Ö ±âºÐ¾ÈÁ¤Á¦(Á¶¿ïÁõ Ä¡·áÁ¦) ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇßÀ¸¸ç, 2024³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2025-2032³â) ½ÃÀå ±Ô¸ð(10¾ï ´Þ·¯)¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR)¿¡ ´ëÇØ Á¶»ç ºÐ¼®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
- ¶ÇÇÑ, ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¼öÀÍ ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.
- ¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ Áß¿äÇÑ °íÂûÀ» Á¦°øÇÕ´Ï´Ù.
- ÀÌ º¸°í¼´Â ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, À繫 ¼º°ú, Àü·« µîÀÇ ¸Å°³ º¯¼ö¸¦ ±â¹ÝÀ¸·Î ¼¼°è ¾ç±Ø¼º Àå¾Ö ±âºÐ ¾ÈÁ¤Á¦ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏÀ» Á¦°øÇÕ´Ï´Ù.
- ÀÌ º¸°í¼ÀÇ ÅëÂû·ÂÀ» ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
- ¾ç±Ø¼º Àå¾Ö ±âºÐ ¾ÈÁ¤Á¦ ¼¼°è ½ÃÀå º¸°í¼´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ½ÃÀå ÁøÃâ±â¾÷, À繫 ºÐ¼®°¡ µî ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.
- ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è ¾ç±Ø¼º Àå¾Ö ±âºÐ ¾ÈÁ¤Á¦ ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ½±°Ô ³»¸± ¼ö ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¸ñÀû°ú ÀüÁ¦Á¶°Ç
Á¦2Àå ½ÃÀå Àü¸Á
Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®
- ½ÃÀå ¿ªÇÐ
- ¼ºÀå ÃËÁø¿äÀÎ
- ¼ºÀå ¾ïÁ¦¿äÀÎ
- ±âȸ
- ¿µÇ⠺м®
- ÁÖ¿ä ¹ßÀü
- ±ÔÁ¦ ½Ã³ª¸®¿À
- Á¦Ç° ¹ß¸Å ¹× ½ÂÀÎ
- PEST ºÐ¼®
- PORTER ºÐ¼®
- ÀμöÇÕº´(M&A) ½Ã³ª¸®¿À
- ¾÷°è µ¿Çâ
Á¦4Àå ¼¼°èÀÇ Á¶¿ïÁõ ±âºÐ ¾ÈÁ¤Á¦ ½ÃÀå, ¾àÁ¦ À¯Çüº°, 2020³â-2032³â
- Lithium
- Lithium Carbonate
- Lithium Citrate
- Anticonvulsants
- Valproic Acid/Valproate/Divalproex Sodium
- Lamotrigine
- Carbamazepine
- Oxcarbazepine
- Topiramate
- Atypical Antipsychotics
- Aripiprazole
- Olanzapine
- Quetiapine
- Risperidone
- Lurasidone
- Ziprasidone
- Asenapine
- Calcium Channel Blockers
- ±âŸ(º´¿ë¿ä¹ý µî)
Á¦5Àå ¼¼°èÀÇ Á¶¿ïÁõ ±âºÐ ¾ÈÁ¤Á¦ ½ÃÀå, ÀûÀÀÁõº°, 2020³â-2032³â
- ¾ç±Ø¼º IÇü Àå¾Ö
- ¾ç±Ø¼º II Àå¾Ö
- ±âºÐ ¼øÈ¯¼º Àå¾Ö
- È¥ÇÕ¼º Á¶¿ïÁõ
- ±Þ¼Ó ¼øÈ¯Çü Á¶¿ïÁõ
- ±âŸ
Á¦6Àå ¼¼°èÀÇ Á¶¿ïÁõ ±âºÐ ¾ÈÁ¤Á¦ ½ÃÀå, Åõ¿© °æ·Îº°, 2020³â-2032³â
- °æ±¸
- ºñ°æ±¸/ÁÖ»çÁ¦
- °æÇÇ
- ±âŸ
Á¦7Àå ¼¼°èÀÇ Á¶¿ïÁõ ±âºÐ ¾ÈÁ¤Á¦ ½ÃÀå, ȯÀÚ ¼Ó¼ºº°, 2020³â-2032³â
- ¿¬·ÉÃþ
- ¾î¸°ÀÌ ¹× û¼Ò³â
- ¼ºÀÎ
- °í·ÉÀÚ
- ¼ºº°
- ³²¼º
- ¿©¼º
Á¦8Àå ¼¼°èÀÇ Á¶¿ïÁõ ±âºÐ ¾ÈÁ¤Á¦ ½ÃÀå, À¯Åë ä³Îº°, 2020³â-2032³â
- º´¿ø ¾à±¹
- ¼Ò¸Å ¾à±¹
- ¿Â¶óÀÎ ¾à±¹
Á¦9Àå ¼¼°èÀÇ Á¶¿ïÁõ ±âºÐ ¾ÈÁ¤Á¦ ½ÃÀå, Áö¿ªº°, 2020³â-2032³â
- ºÏ¹Ì
- ¶óƾ¾Æ¸Þ¸®Ä«
- ºê¶óÁú
- ¾Æ¸£ÇîÆ¼³ª
- ¸ß½ÃÄÚ
- ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
- À¯·´
- µ¶ÀÏ
- ¿µ±¹
- ½ºÆäÀÎ
- ÇÁ¶û½º
- ÀÌÅ»¸®¾Æ
- ·¯½Ã¾Æ
- ±âŸ À¯·´
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- Áß±¹
- Àεµ
- ÀϺ»
- È£ÁÖ
- Çѱ¹
- ASEAN
- ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
- 秵- GCC ±¹°¡
- À̽º¶ó¿¤
- ±âŸ Áßµ¿
- ¾ÆÇÁ¸®Ä«
- ³²¾ÆÇÁ¸®Ä«
- ºÏ¾ÆÇÁ¸®Ä«
- Áß¾Ó¾ÆÇÁ¸®Ä«
Á¦10Àå °æÀï ±¸µµ
- Eli Lilly and Company
- AstraZeneca PLC
- Johnson & Johnson
- Pfizer Inc.
- AbbVie Inc.
- Bristol-Myers Squibb
- GlaxoSmithKline
- Sanofi S.A.
- Merck & Co.
- Teva Pharmaceutical Industries
- Novartis AG
- Otsuka Pharmaceutical
- Lundbeck A/S
- Takeda Pharmaceutical Company
- Alkermes plc
Á¦11Àå ¾Ö³Î¸®½ºÆ®ÀÇ Á¦¾È
- Wheel of Fortune
- ¾Ö³Î¸®½ºÆ®ÀÇ °ßÇØ
- Coherent Opportunity Map
Á¦12Àå Âü°í ¹®Çå°ú Á¶»ç ¹æ¹ý
- Âü°í ¹®Çå
- Á¶»ç ¹æ¹ý
- ÃâÆÇ»ç¿¡ ´ëÇØ
LSH
¿µ¹® ¸ñÂ÷
The Global Bipolar Disorder Mood Stabilizers Market is estimated to be valued at USD 2.22 Bn in 2025 and is expected to reach USD 2.64 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 2.5% from 2025 to 2032.
Report Coverage |
Report Details |
Base Year: |
2024 |
Market Size in 2025: |
USD 2.22 Bn |
Historical Data for: |
2020 To 2024 |
Forecast Period: |
2025 To 2032 |
Forecast Period 2025 to 2032 CAGR: |
2.50% |
2032 Value Projection: |
USD 2.64 Bn |
Bipolar disorder, also known as manic-depressive illness, is a brain disorder that causes unusual shifts in mood, energy, activity levels, and the ability to carry out day-to-day tasks. Mood stabilizers are a class of drugs used to prevent or treat the extreme mood swings associated with bipolar disorder. The global bipolar disorder mood stabilizers market has been gaining significant traction over the past few years, owing to the rising prevalence of bipolar disorder worldwide and growing awareness regarding its effective treatment options. Increasing R&D investments by pharmaceutical companies to develop novel treatment alternatives are also propelling the market growth.
Market Dynamics
The global bipolar disorder mood stabilizers market is primarily driven by the growing prevalence of bipolar disorder caused by genetic and environmental factors such as traumatic life events and substance abuse. As per WHO statistics released in July 2024, over 45 million people worldwide suffer from bipolar disorder. Furthermore, rising awareness about available treatment options and increased healthcare spending are encouraging more patients to seek medical help. Meanwhile, continuous innovations and introduction of new drug formulations with higher efficacy and improved tolerability are helping expand the market reach. However, the market potential is still untapped in underdeveloped economies due to low diagnosis and treatment rates of mental disorders. High costs of branded drugs also limit their adoption in price-sensitive markets. Nonetheless, ongoing clinical trials for advanced drugs, especially for treatment-resistant patients, are expected to introduce new opportunities during the forecast period.
Key Features of the Study
- This report provides in-depth analysis of the global bipolar disorder mood stabilizers market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global bipolar disorder mood stabilizers market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Eli Lilly and Company, AstraZeneca PLC, Johnson & Johnson, Pfizer Inc., AbbVie Inc., Bristol-Myers Squibb, GlaxoSmithKline, Sanofi S.A., Merck & Co., Teva Pharmaceutical Industries, Novartis AG, Otsuka Pharmaceutical, H. Lundbeck A/S, Takeda Pharmaceutical Company, and Alkermes plc
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global bipolar disorder mood stabilizers market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bipolar disorder mood stabilizers market
Market Segmentation
- Drug Type Insights (Revenue, USD Bn, 2020 - 2032)
- Lithium
- Lithium Carbonate
- Lithium Citrate
- Anticonvulsants
- Valproic Acid/Valproate/Divalproex Sodium
- Lamotrigine
- Carbamazepine
- Oxcarbazepine
- Topiramate
- Atypical Antipsychotics
- Aripiprazole
- Olanzapine
- Quetiapine
- Risperidone
- Lurasidone
- Ziprasidone
- Asenapine
- Calcium Channel Blockers
- Others (Combination Therapies, etc.)
- Indication Insights (Revenue, USD Bn, 2020 - 2032)
- Bipolar I Disorder
- Bipolar II Disorder
- Cyclothymic Disorder
- Mixed Features Bipolar Disorder
- Rapid Cycling Bipolar Disorder
- Others
- Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Oral
- Parenteral/Injectable
- Transdermal
- Others
- Patient Demographics Insights (Revenue, USD Bn, 2020 - 2032)
- Age Groups
- Children and adolescents
- Adults
- Elderly
- Gender
- Male
- Female
- Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Eli Lilly and Company
- AstraZeneca PLC
- Johnson & Johnson
- Pfizer Inc.
- AbbVie Inc.
- Bristol-Myers Squibb
- GlaxoSmithKline
- Sanofi S.A.
- Merck & Co.
- Teva Pharmaceutical Industries
- Novartis AG
- Otsuka Pharmaceutical
- Lundbeck A/S
- Takeda Pharmaceutical Company
- Alkermes plc
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Bipolar Disorder Mood Stabilizers Market, By Drug Type
- Global Bipolar Disorder Mood Stabilizers Market, By Indication
- Global Bipolar Disorder Mood Stabilizers Market, By Route of Administration
- Global Bipolar Disorder Mood Stabilizers Market, By Patient Demographics
- Global Bipolar Disorder Mood Stabilizers Market, By Distribution Channel
- Global Bipolar Disorder Mood Stabilizers Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Bipolar Disorder Mood Stabilizers Market, By Drug Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Lithium
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Lithium Carbonate
- Lithium Citrate
- Anticonvulsants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Valproic Acid/Valproate/Divalproex Sodium
- Lamotrigine
- Carbamazepine
- Oxcarbazepine
- Topiramate
- Atypical Antipsychotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Aripiprazole
- Olanzapine
- Quetiapine
- Risperidone
- Lurasidone
- Ziprasidone
- Asenapine
- Calcium Channel Blockers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others (Combination Therapies, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Bipolar Disorder Mood Stabilizers Market, By Indication, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Bipolar I Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Bipolar II Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Cyclothymic Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Mixed Features Bipolar Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Rapid Cycling Bipolar Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Bipolar Disorder Mood Stabilizers Market, By Route of Administration, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Parenteral/Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Transdermal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Bipolar Disorder Mood Stabilizers Market, By Patient Demographics, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Age Groups
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Children and adolescents
- Adults
- Elderly
- Gender
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Male
- Female
8. Global Bipolar Disorder Mood Stabilizers Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Bipolar Disorder Mood Stabilizers Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Latin America
- Introduction
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
10. Competitive Landscape
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Otsuka Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Lundbeck A/S
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Alkermes plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
11. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
12. References and Research Methodology
- References
- Research Methodology
- About us
°ü·ÃÀÚ·á